TSHA - NASDAQ
Taysha Gene Therapies, Inc.
$5.79
+1.7%Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
At a Glance
Live Snapshottsha
Property, Plant, and Equipment (Net)
Last Annual Value
16.18M
3-Year CAGR
-15%
5-Year CAGR
124%
10-Year CAGR
%
Taysha Gene Therapies, Inc. Competitors Analysis of Property, Plant, and Equipment (Net)
| Company | Property, Plant, and Equipment (Net) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Taysha Gene Therapies, Inc. NASDAQ:TSHA | 16.18M | -7.5% | -20.4% | N/A | |
 Atai Beckley Inc. NASDAQ:ATAI | 4.01M | 22.1% | 93.2% | N/A | |
 Nektar Therapeutics NASDAQ:NKTR | 5.00M | -48.6% | -51.0% | -22.7% | |
 Dianthus Therapeutics, Inc. NASDAQ:DNTH | 1.63M | 26.9% | -26.2% | 12.4% | |
 Xencor, Inc. NASDAQ:XNCR | 90.90M | -3.2% | 8.7% | 40.2% | |
 Enliven Therapeutics, Inc. NASDAQ:ELVN | 417.00K | -26.8% | -15.3% | N/A | |
 AnaptysBio, Inc. NASDAQ:ANAB | 13.89M | -8.7% | -8.7% | 40.3% | |
 Sana Biotechnology, Inc. NASDAQ:SANA | 65.22M | -23.5% | -16.6% | N/A | |
 BridgeBio Oncology Therapeutics Inc. NASDAQ:BBOT | 0.00 | N/A | N/A | N/A |
Taysha Gene Therapies, Inc. Fair Value Envelope
Related Guides
Continue your TSHA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.